Sequencing of tumor-specific CD8+ T cells revealed that anti-VISTA therapy activated T-cell pathways highly distinct from, and complementary to, those activated by anti-PD-1 therapy, with VISTA-targeting therapy reducing the regulators of T-cell quiescence (42). Here, CD8A is linked to neoplasm.